Diagnósticos da América (DASA3) Q4 2024 earnings summary

Executive summary

• 2024 marked a transformation with strategic repositioning, including the sale of non-core units for BRL 250–255 million and a joint venture with Amil, creating Brazil's largest hospital platform.

• Operational excellence initiatives led to productivity gains, higher NPS, cost reductions, and improved process standardization.

• Team reorganization and business segregation are nearly complete, enabling focused management and faster deleveraging.

• Capital structure improved, with net financial debt/EBITDA reduced to 4.08x and cash balance double the debts due by end-2025.

• Net result was a loss of BRL 1.2 billion in 2024, mainly due to higher financial expenses.

Financial highlights

• Gross revenue reached BRL 16.8 billion in 2024, up 8% year-over-year; adjusted gross profit rose 11% to BRL 4.5 billion.

• EBITDA for 2024 was BRL 2.5 billion, up 11% year-over-year; margin increased 0.6 percentage points to 16.1%.

• Excluding non-recurring items, EBITDA growth reached 23% for the year.

• Operating cash generation reached BRL 910 million, 2.5 times higher than 2023.

• CapEx for 2024 was BRL 547 million, down 25% year-over-year, with a focus on technology and expansion.

Outlook and guidance

• Management expects further deleveraging and improved cash flow through operational plans, working capital enhancements, and the Amil JV closing.

• Continued focus on cost reduction, asset optimization, and margin improvement in both business units.

• Ongoing separation of hospital and diagnostics businesses to unlock further efficiencies.

• The company anticipates capturing synergies from the joint operation, boosting results and reducing leverage.